Faeth Therapeutics, Inc. Investment Income, Net
Faeth Therapeutics, Inc. (FTH) reported Investment Income, Net of $2.26 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2026-08-04
- Faeth Therapeutics, Inc. investment income, net for the quarter ending 2026-06-30 was $2.26M, a 626.05% increase year-over-year.
- Faeth Therapeutics, Inc. investment income, net for the quarter ending 2026-03-31 was $392.00K, a 0.00% change year-over-year.
- Faeth Therapeutics, Inc. investment income, net for the quarter ending 2025-12-31 was $223.00K, a 57.28% decline year-over-year.
- Faeth Therapeutics, Inc. investment income, net for the quarter ending 2025-09-30 was $289.00K, a 51.10% decline year-over-year.
- Faeth Therapeutics, Inc. investment income, net for fiscal 2025 was $1.24M, a 51.41% decline from fiscal 2024.
- Faeth Therapeutics, Inc. investment income, net for fiscal 2024 was $2.55M, a 29.64% decline from fiscal 2023.
- Faeth Therapeutics, Inc. investment income, net for fiscal 2023 was $3.62M, a 103.25% increase from fiscal 2022.
- Faeth Therapeutics, Inc. investment income, net for fiscal 2022 was $1.78M, a 122.87% increase from fiscal 2021.
| Period end | Investment Income, Net 3 month | Investment Income, Net 3 month as first filed | Investment Income, Net 6 month | Investment Income, Net 6 month as first filed | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.26M 10-Q · filed 2026-08-04 | $2.65M 10-Q · filed 2026-08-04 | $2.87M derived: sum of 3 quarters · filed 2026-08-04 | $3.16M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $392.00K 10-Q · filed 2026-05-15 | $615.00K derived: sum of 2 quarters · filed 2026-05-15 | $904.00K derived: sum of 3 quarters · filed 2026-05-15 | $1.22M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | $223.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $512.00K derived: sum of 2 quarters · filed 2026-03-30 | $823.00K derived: sum of 3 quarters · filed 2026-08-04 | $1.24M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | $289.00K 10-Q · filed 2025-11-14 | $600.00K derived: sum of 2 quarters · filed 2026-08-04 | $1.02M 10-Q · filed 2025-11-14 | $1.51M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-30 | $311.00K 10-Q · filed 2026-08-04 | $321.00K 10-Q · filed 2025-08-05 | $703.00K 10-Q · filed 2026-08-04 | $726.00K 10-Q · filed 2025-08-05 | $1.23M derived: sum of 3 quarters · filed 2026-08-04 | $1.82M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $392.00K 10-Q · filed 2026-05-15 | $405.00K 10-Q · filed 2025-05-06 | $914.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.50M derived: sum of 3 quarters · filed 2026-05-15 | $2.17M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $522.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.11M derived: sum of 2 quarters · filed 2026-03-30 | $1.78M derived: sum of 3 quarters · filed 2026-03-30 | $2.55M 10-K · filed 2026-03-30 | ||
| 2024-09-30 | $591.00K 10-Q · filed 2025-11-14 | $1.26M derived: sum of 2 quarters · filed 2025-11-14 | $2.03M 10-Q · filed 2025-11-14 | $2.85M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $669.00K 10-Q · filed 2025-08-05 | $1.44M 10-Q · filed 2025-08-05 | $2.26M derived: sum of 3 quarters · filed 2025-08-05 | $3.14M derived: sum of 4 quarters · filed 2025-08-05 | ||
| 2024-03-31 | $768.00K 10-Q · filed 2025-05-06 | $1.59M derived: sum of 2 quarters · filed 2025-05-06 | $2.47M derived: sum of 3 quarters · filed 2025-05-06 | $3.42M derived: sum of 4 quarters · filed 2025-05-06 | ||
| 2023-12-31 | $826.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $1.70M derived: sum of 2 quarters · filed 2025-03-28 | $2.65M derived: sum of 3 quarters · filed 2025-03-28 | $3.62M 10-K · filed 2025-03-28 | ||
| 2023-09-30 | $877.00K 10-Q · filed 2024-11-14 | $1.83M derived: sum of 2 quarters · filed 2024-11-14 | $2.80M 10-Q · filed 2024-11-14 | $3.41M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $952.00K 10-Q · filed 2024-08-06 | $1.92M 10-Q · filed 2024-08-06 | $2.53M derived: sum of 3 quarters · filed 2024-08-06 | $3.04M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $969.00K 10-Q · filed 2024-05-09 | $1.58M derived: sum of 2 quarters · filed 2024-05-09 | $2.09M derived: sum of 3 quarters · filed 2024-05-09 | $2.44M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $609.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.12M derived: sum of 2 quarters · filed 2024-02-29 | $1.47M derived: sum of 3 quarters · filed 2024-02-29 | $1.78M 10-K · filed 2024-02-29 | ||
| 2022-09-30 | $515.00K 10-Q · filed 2023-11-07 | $864.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.17M 10-Q · filed 2023-11-07 | $1.51M derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $349.00K 10-Q · filed 2023-08-03 | $659.00K 10-Q · filed 2023-08-03 | $993.00K derived: sum of 3 quarters · filed 2023-08-03 | $1.27M derived: sum of 4 quarters · filed 2023-08-03 | ||
| 2022-03-31 | $310.00K 10-Q · filed 2023-05-09 | $644.00K derived: sum of 2 quarters · filed 2023-05-09 | $922.00K derived: sum of 3 quarters · filed 2023-05-09 | $1.11M derived: sum of 4 quarters · filed 2023-05-09 | ||
| 2021-12-31 | $334.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $612.00K derived: sum of 2 quarters · filed 2023-03-29 | $800.00K derived: sum of 3 quarters · filed 2023-03-29 | $800.00K 10-K · filed 2023-03-29 | ||
| 2021-09-30 | $278.00K 10-Q · filed 2022-11-08 | $466.00K derived: sum of 2 quarters · filed 2022-11-08 | $466.00K 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $188.00K 10-Q · filed 2022-08-09 | $188.00K 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |